手法を比較
選択した手法を並べて確認できます。異なる行はハイライト表示されます。
| 乾癬面積重症度指数(PASI)× | EASI(アトピー性皮膚炎面積・重症度指数)× | |
|---|---|---|
| 分野 | 皮膚科学 | 皮膚科学 |
| 系統 | Process / pipeline | Process / pipeline |
| 提唱年≠ | 1978 | 2001 |
| 提唱者≠ | Fredriksson T, Pettersson U | Hanifin JM, Thurston M |
| 種類 | Clinician-rated | Clinician-rated |
| 原典≠ | Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-244. DOI ↗ | Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Experimental Dermatology. 2001;10(1):11-18. DOI ↗ |
| 別名 | PASI Index | EASI Index |
| 関連 | 2 | 2 |
| 概要≠ | The PASI is the gold-standard clinician-administered measure of psoriasis severity and extent. Developed by Fredriksson and Pettersson in 1978, it evaluates four cardinal clinical signs (erythema, induration, desquamation) across four body regions, each weighted by anatomical importance. PASI is the most widely used endpoint in psoriasis clinical trials and is endorsed by regulatory agencies (FDA, EMA) and international dermatology societies. | The EASI is a structured, clinician-administered tool for assessing the extent and intensity of atopic dermatitis across the body. Developed by Hanifin and colleagues in 2001, it divides the body into four regions with weighted area factors, ensuring proportional contribution to total score. EASI has become the primary objective severity measure in atopic dermatitis clinical trials and is recommended by international regulatory authorities (FDA, EMA). |
| ScholarGateデータセット ↗ |
|
|